News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,684 Results
Type
Article (776)
Company Profile (18)
Press Release (12889)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4491)
Career Advice (17)
Deals (654)
Drug Delivery (2)
Drug Development (2334)
Employer Resources (2)
FDA (221)
Job Trends (277)
News (7240)
Policy (382)
Tag
Academia (37)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1213)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (20)
Approvals (215)
Artificial intelligence (7)
Autoimmune disease (6)
Bankruptcy (4)
Best Places to Work (219)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (2)
Cancer (123)
Cardiovascular disease (12)
Career advice (10)
CAR-T (16)
CDC (1)
Cell therapy (56)
Clinical research (1877)
Collaboration (63)
Compensation (34)
Complete response letters (4)
COVID-19 (103)
CRISPR (7)
C-suite (41)
Cystic fibrosis (1)
Data (169)
Diabetes (13)
Diagnostics (32)
Drug discovery (9)
Drug pricing (1)
Earnings (1496)
Editorial (2)
Employer resources (2)
Events (2532)
Executive appointments (50)
FDA (293)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (48)
Gene editing (12)
Gene therapy (38)
GLP-1 (19)
Government (52)
Guidances (7)
Healthcare (386)
Immunology and inflammation (13)
Immuno-oncology (1)
Infectious disease (105)
Inflammatory bowel disease (10)
Intellectual property (6)
Interviews (3)
IPO (363)
Job creations (62)
Job search strategy (10)
JPM (2)
Kidney cancer (1)
Labor market (5)
Layoffs (20)
Legal (65)
Liver cancer (2)
Lung cancer (16)
Lymphoma (21)
Machine learning (1)
Management (1)
Manufacturing (29)
MASH (2)
Medical device (66)
Medtech (66)
Mergers & acquisitions (320)
Metabolic disorders (21)
Neurodegenerative disease (8)
Neuroscience (27)
NextGen: Class of 2026 (139)
Non-profit (19)
Now hiring (1)
Obesity (6)
Opinion (1)
Ovarian cancer (4)
Pain (9)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (11)
Patient recruitment (9)
People (1753)
Pharmacy benefit managers (1)
Phase 1 (855)
Phase 2 (918)
Phase 3 (541)
Pipeline (145)
Policy (14)
Postmarket research (25)
Preclinical (285)
Press Release (1)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (38)
Real estate (115)
Recruiting (1)
Regulatory (383)
Reports (3)
Research institute (63)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (12)
Series B (4)
Service/supplier (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (105)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (16)
Venture capital (4)
Weight loss (3)
Date
Last 7 days (20)
Last 30 days (57)
Last 365 days (816)
2026 (76)
2025 (837)
2024 (1023)
2023 (1264)
2022 (1594)
2021 (1625)
2020 (1242)
2019 (731)
2018 (540)
2017 (661)
2016 (546)
2015 (591)
2014 (397)
2013 (339)
2012 (292)
2011 (296)
2010 (310)
Location
Africa (16)
Asia (1116)
Australia (91)
California (503)
Canada (123)
China (35)
Colorado (3)
Connecticut (9)
Delaware (14)
Europe (1313)
Florida (33)
Idaho (1)
Illinois (7)
India (9)
Indiana (2)
Japan (16)
Maryland (64)
Massachusetts (226)
Michigan (4)
Minnesota (5)
Nevada (1)
New Jersey (73)
New Mexico (1)
New York (40)
North Carolina (18)
Northern California (221)
Oklahoma (1)
Pennsylvania (68)
South America (9)
Southern California (191)
Texas (38)
United States (1102)
Utah (2)
Virginia (1)
Washington D.C. (2)
Washington State (17)
Wisconsin (2)
13,684 Results for "capsida biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy.
September 11, 2025
·
2 min read
·
Tristan Manalac
Business
Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer
Capsida Biotherapeutics today announced the promotion of Rob Murphy to Chief Manufacturing and Quality Officer.
March 12, 2024
·
3 min read
Biotech Bay
Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the Evercore ISI 2024 Emerging Biotech Conference which is being held virtually February 28-29, 2024.
February 21, 2024
·
1 min read
Press Releases
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
November 25, 2024
·
1 min read
Press Releases
Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 19, 2024
·
1 min read
Drug Development
Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations
Capsida Biotherapeutics announced new preclinical data supporting the potential of Capsida’s gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 mutations.
May 7, 2024
·
6 min read
Drug Development
Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration
Capsida Biotherapeutics announced new preclinical data that demonstrate the potential of its next-generation intravenously administered gene therapy candidate, CAP-003, to safely and effectively treat Parkinson’s disease associated with GBA mutations.
May 10, 2024
·
4 min read
Biotech Beach
Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa
Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences.
September 20, 2023
·
1 min read
Business
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. (“Capsida”) and Kate Therapeutics (“KateTx”) today announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
October 3, 2023
·
3 min read
Press Releases
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations
June 11, 2025
·
3 min read
1 of 1,369
Next
